{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:55:43Z","timestamp":1773212143442,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.rdc.2014.01.012","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T15:01:24Z","timestamp":1392908484000},"page":"357-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long-Term Management of Gout"],"prefix":"10.1016","volume":"40","author":[{"given":"Yashaar","family":"Chaichian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2014.01.012_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","article-title":"Gout and hyperuricemia","volume":"14","author":"Wortmann","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib4","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A\u00a0retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction in tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2014.01.012_bib9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"The required for disappearance of urate crystals from synovial fluid after successful hyperuricemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK General Practice Research Database, 1990-1999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib11","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib12","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1001\/jama.1991.03470210072035","article-title":"Incidence and risk factors for gout in white men","volume":"266","author":"Roubenoff","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2014.01.012_bib13","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population","volume":"31","author":"Wallace","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.1780380508","article-title":"Racial differences in the incidence of gout. The role of hypertension","volume":"38","author":"Hochberg","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0049-0172(75)90002-5","article-title":"Gout in Maoris","volume":"5","author":"Rose","year":"1975","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib16","first-page":"1364","article-title":"High prevalence of gout and related risk factors in Taiwan\u2019s Aborigines","volume":"24","author":"Chang","year":"1997","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/art.27338","article-title":"Epidemiology of gout in women: fifty-two-year followup of a prospective cohort","volume":"62","author":"Bhole","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/rheumatology\/keg422","article-title":"Trends in the manifestations of gout in Taiwan","volume":"42","author":"Chen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2014.01.012_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s10067-006-0527-4","article-title":"Manifestations of metabolic syndrome associated with male gout in different age strata","volume":"26","author":"Chen","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals\u2019 Follow-Up Study","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib21","first-page":"43","article-title":"High prevalence of gout in patients with type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors","volume":"121","author":"Suppiah","year":"2008","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.rdc.2014.01.012_bib22","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib23","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for the management of gout. Part 1: systemic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib24","series-title":"UpToDate","article-title":"Prevention of recurrent gout","author":"Becker","year":"2014"},{"key":"10.1016\/j.rdc.2014.01.012_bib25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2014.01.012_bib26","first-page":"1501","article-title":"The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study","volume":"27","author":"Lin","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/ajcn\/78.4.690","article-title":"A\u00a0case-control study of the association of diet and obesity with gout in Taiwan","volume":"78","author":"Lyu","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.rdc.2014.01.012_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-277X.2008.00928.x","article-title":"The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence","volume":"22","author":"Shulten","year":"2009","journal-title":"J\u00a0Hum Nutr Diet"},{"key":"10.1016\/j.rdc.2014.01.012_bib29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib30","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ajcn\/87.5.1480","article-title":"Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men","volume":"87","author":"Williams","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.rdc.2014.01.012_bib31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.22762","article-title":"Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey","volume":"57","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib32","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/art.22712","article-title":"Coffee consumption and risk of incident gout in men: a prospective study","volume":"56","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib33","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1002\/art.34677","article-title":"Cherry consumption and decreased risk of recurrent gout attacks","volume":"64","author":"Zhang","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: a prospective study","volume":"336","author":"Choi","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.rdc.2014.01.012_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.23245","article-title":"Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey","volume":"59","author":"Choi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2014.01.012_bib36","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/annrheumdis-2012-202732","article-title":"Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load","volume":"72","author":"Dalbeth","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib37","first-page":"1341","article-title":"Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover study","volume":"33","author":"Hunter","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/01.tp.0000188722.84775.af","article-title":"New-onset gout after kidney transplantation: incidence, risk factors and implications","volume":"80","author":"Abbot","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.rdc.2014.01.012_bib39","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI103905","article-title":"Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man","volume":"38","author":"Yu","year":"1959","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.rdc.2014.01.012_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C","article-title":"The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients","volume":"43","author":"Caspi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib41","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.rdc.2014.01.012_bib42","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjmed.2012.05.025","article-title":"Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial","volume":"125","author":"Taylor","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib43","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A\u00a0two-stage approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib44","first-page":"1383","article-title":"Withdrawal of longterm antihyperuricemic therapy in tophaceous gout","volume":"20","author":"Van Lieshout-Zuidema","year":"1993","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF02201004","article-title":"Withdrawal of longterm antihyperuricemic therapy in tophaceous gout","volume":"6","author":"Gast","year":"1987","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.rdc.2014.01.012_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib49","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J\u00a0Mol Evol"},{"key":"10.1016\/j.rdc.2014.01.012_bib51","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0891-5849(02)00956-5","article-title":"Structure and function of xanthine oxidoreductase: where are we now?","volume":"33","author":"Harrison","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rdc.2014.01.012_bib53","unstructured":"US National Library of Medicine DailyMed: FDA information: allopurinol tablet. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?startswith=allopurinol. Accessed August 24, 2013."},{"key":"10.1016\/j.rdc.2014.01.012_bib54","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2014.01.012_bib55","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2014.01.012_bib56","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenetic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib57","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib58","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib59","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2014.01.012_bib60","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib61","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib62","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.01.012_bib63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rdc.2014.01.012_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib65","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.rdc.2014.01.012_bib66","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.rdc.2012.08.008","article-title":"Safety of urate-lowering therapies: managing the risks to gain the benefits","volume":"38","author":"Keenan","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rdc.2014.01.012_bib67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A\u00a0critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2014.01.012_bib68","first-page":"1361","article-title":"Severe allopurinol hypersensitivity syndrome","volume":"72","author":"Lupton","year":"1979","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib69","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rdc.2014.01.012_bib70","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.rdc.2014.01.012_bib71","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.rdc.2014.01.012_bib72","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0002-9343(92)90236-5","article-title":"Desensitization to allopurinol in patients with gout and cutaneous reactions","volume":"93","author":"Fam","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib73","unstructured":"US National Library of Medicine DailyMed: FDA information: febuxostat tablet. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?startswith=febuxostat. Accessed August 24, 2013."},{"key":"10.1016\/j.rdc.2014.01.012_bib74","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3899\/jrheum.101156","article-title":"Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors","volume":"38","author":"Goldfarb","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: five-year findings of the FOCUS Efficacy and Safety Study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2014.01.012_bib76","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A\u00a0randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 330-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib77","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib78","unstructured":"ClinicalTrials.gov. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES). Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01101035?term=allopurinol+febuxostat&rank=4. Accessed September 21, 2013."},{"key":"10.1016\/j.rdc.2014.01.012_bib79","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1440-1746.2010.06254.x","article-title":"Azathioprine and allopurinol: a two-edged interaction","volume":"25","author":"Gearry","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib80","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1600-0773.1980.tb02472.x","article-title":"The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol","volume":"46","author":"Witten","year":"1980","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1016\/j.rdc.2014.01.012_bib81","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.metabol.2011.08.005","article-title":"Uric acid excretion in normal subjects: a nomogram to assess the mechanisms underlying purine metabolic disorders","volume":"61","author":"Puig","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.rdc.2014.01.012_bib82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.rdc.2014.01.012_bib83","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a\u00a0voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans","volume":"283","author":"Anzai","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rdc.2014.01.012_bib84","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/ken460","article-title":"Crystal ball gazing: new therapeutic targets for hyperuricemia and gout","volume":"48","author":"Dalbeth","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2014.01.012_bib85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib86","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A\u00a0benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.rdc.2014.01.012_bib87","first-page":"467","article-title":"Studies on the metabolism of D-penicillamine and its interaction with probenecid in cystinuria and rheumatoid arthritis","volume":"11","author":"Yu","year":"1984","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.01.012_bib88","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","article-title":"Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout","volume":"42","author":"Feher","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2014.01.012_bib90","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archinternmed.2008.606","article-title":"Vitamin C intake and the risk of gout in men: a prospective study","volume":"169","author":"Choi","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2014.01.012_bib91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.rdc.2014.01.012_bib92","unstructured":"Krystexxa TM. Prescribing information 2013. Available at: http:\/\/krystexxa.com\/pdfs\/krystexxa prescribing information.pdf. Accessed September 21, 2013."},{"key":"10.1016\/j.rdc.2014.01.012_bib93","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to conventional treatment","volume":"72","author":"Becker","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.01.012_bib94","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"J\u00a0Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X14000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X14000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:13:35Z","timestamp":1760181215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X14000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0889857X14000131"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2014.01.012","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Management of Gout","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2014.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}